Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy

E-ISSN： 1873-5592|14|4|490-496

ISSN： 1389-4501

Source： Current Drug Targets, Vol.14, Iss.4, 2013-04, pp. : 490-496

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Sulodexide in the Treatment of Diabetic Nephropathy

By Weiss Ram

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2681-2696

Adis International

Access to resources Recommend Favorite

Agents in development for the treatment of diabetic nephropathy

By Fukami Kei Cooper Mark E Forbes Josephine M

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 3, 2005-03 ,pp. : 279-294

Informa Healthcare

Access to resources Recommend Favorite

Targeting NO Signaling for the Treatment of Osteoporosis

Current Medicinal Chemistry, Vol. 23, Iss. 24, 2016-08 ,pp. : 2746-2753

Bentham Science Publishers

Access to resources Recommend Favorite

Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic Nephropathy

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 12, Iss. 3, 2013-06 ,pp. : 153-161

Bentham Science Publishers

Access to resources Recommend Favorite

A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy

By Thomas Merlin

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 8, 2012-08 ,pp. : 1015-1022

Informa Healthcare

Access to resources Recommend Favorite